Literature DB >> 12359621

Designer pharmacotherapy for the treatment of cystic fibrosis: commentary on Zegarra-Moran et al.

M A Gray1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12359621      PMCID： PMC1573509          DOI： 10.1038/sj.bjp.0704883

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  11 in total

1.  The CF salt controversy: in vivo observations and therapeutic approaches.

Authors:  R Tarran; B R Grubb; D Parsons; M Picher; A J Hirsh; C W Davis; R C Boucher
Journal:  Mol Cell       Date:  2001-07       Impact factor: 17.970

2.  ATP hydrolysis by a CFTR domain: pharmacology and effects of G551D mutation.

Authors:  L D Howell; R Borchardt; J A Cohn
Journal:  Biochem Biophys Res Commun       Date:  2000-05-10       Impact factor: 3.575

3.  Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds.

Authors:  L J Galietta; M F Springsteel; M Eda; E J Niedzinski; K By; M J Haddadin; M J Kurth; M H Nantz; A S Verkman
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

Review 4.  Pharmacotherapy of the ion transport defect in cystic fibrosis.

Authors:  K Kunzelmann; M Mall
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-11       Impact factor: 2.557

5.  Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.

Authors:  B Illek; L Zhang; N C Lewis; R B Moss; J Y Dong; H Fischer
Journal:  Am J Physiol       Date:  1999-10

6.  Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation.

Authors:  R Dérand; L Bulteau-Pignoux; Y Mettey; O Zegarra-Moran; L D Howell; C Randak; L J Galietta; J A Cohn; C Norez; L Romio; J M Vierfond; M Joffre; F Becq
Journal:  Am J Physiol Cell Physiol       Date:  2001-11       Impact factor: 4.249

Review 7.  Pharmacology of CFTR chloride channel activity.

Authors:  B D Schultz; A K Singh; D C Devor; R J Bridges
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

8.  cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein.

Authors:  B Illek; H Fischer; G F Santos; J H Widdicombe; T E Machen; W W Reenstra
Journal:  Am J Physiol       Date:  1995-04

9.  Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells.

Authors:  R L Dormer; R Dérand; C M McNeilly; Y Mettey; L Bulteau-Pignoux; T Métayé; J M Vierfond; M A Gray; L J Galietta; M R Morris; M M Pereira; I J Doull; F Becq; M A McPherson
Journal:  J Cell Sci       Date:  2001-11       Impact factor: 5.285

10.  Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07.

Authors:  Olga Zegarra-Moran; Leila Romio; Chiara Folli; Emanuela Caci; Frederic Becq; Jean-Michel Vierfond; Yvette Mettey; Giulio Cabrini; Pascale Fanen; Luis J V Galietta
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.